Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28734482 | 0.90 | HSD17B10 (0.37) | HSD11B1HSD17B10GAATDP1KDM4E | |
| SCHEMBL6043536 | 0.88 | HSD17B10 (0.38) | HSD11B1HSD17B10GAAHRH1KDM4E | |
| SCHEMBL6043797 | 0.86 | ALDH1A1 (0.40) | HSD17B10GAATDP1KDM4EALDH1A1 | |
| SCHEMBL4893194 | 0.82 | HSD11B1 (0.47) | HSD11B1KDM1ATDP1ACHEKDM4E | |
| SCHEMBL8149011 | 0.82 | HSD11B1 (0.47) | HSD11B1KDM1ATDP1ACHEKDM4E | |
| SCHEMBL6057032 | 0.82 | — | — | |
| SCHEMBL27887365 | 0.81 | HSD11B1 (0.39) | HSD11B1NAMPTKDM1ATDP1ACHE | |
| SCHEMBL9534288 | 0.80 | HSD17B10 (0.38) | HSD17B10GAATDP1KDM4EALDH1A1 | |
| SCHEMBL23051090 | 0.79 | HSD17B10 (0.40) | HSD17B10GAA | |
| SCHEMBL3939913 | 0.79 | HSD11B1 (0.41) | HSD11B1NAMPTTDP1ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | claimed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | claimed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | claimed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | claimed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | claimed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | claimed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20080108610-A1 | Selected Benzofuran Derivatives | ARPIDA AG (CH) | 2008-05-08 | — | — | US | claimed |
| EP-1838704-A1 | SELECTED BENZOFURAN DERIVATIVES | Arpida AG (CH) | 2007-10-03 | — | — | EP | claimed |
| WO-2006072370-A1 | SELECTED BENZOFURAN DERIVATIVES | ARPIDA AG (CH) | 2006-07-13 | — | — | WO | claimed |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-1838704-A1 | SELECTED BENZOFURAN DERIVATIVES | Arpida AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072370-A1 | SELECTED BENZOFURAN DERIVATIVES | ARPIDA AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| EP-0839805-B1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | SCHERING AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-5969138-A | ANTIPSYCHOTIC AGENTS | MITSUI CHEMICALS, INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0839805-A1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | HSD11B1 629/4885HSD17B10 3840/4885GAA 406/4885 |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | HSD11B1 959/4885HSD17B10 2946/4885GAA 561/4885 |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | HSD11B1 3067/4885HSD17B10 4313/4885GAA 1651/4885 |
| US-20080108610-A1 | Selected Benzofuran Derivatives | ABCG2, BPTF, SBDS | HSD11B1 2907/4885HSD17B10 1129/4885GAA 328/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | HSD11B1 956/4885HSD17B10 2940/4885GAA 547/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | HSD11B1 956/4885HSD17B10 2940/4885GAA 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.